Immutep Announced Early Monday It Selected Charles River Laboratories for IMP761's GLP Toxicology Study
Portfolio Pulse from Charles Gross
Immutep has entered into an agreement with Charles River Laboratories for a GLP toxicology study of its proprietary preclinical candidate IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.
May 29, 2023 | 10:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories has been selected by Immutep to conduct a GLP toxicology study for its autoimmune disease candidate IMP761.
Charles River Laboratories being selected by Immutep for the GLP toxicology study of IMP761 demonstrates the company's expertise and could lead to more partnerships in the future. This could have a positive impact on Charles River's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Immutep partners with Charles River Laboratories for a GLP toxicology study of its autoimmune disease candidate IMP761.
The partnership with Charles River Laboratories will help Immutep advance its preclinical candidate IMP761, potentially leading to positive developments in its autoimmune disease treatment. This could positively impact Immutep's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100